CN1125725A - First-kind "Haikelin" alkali derivant and its usage - Google Patents

First-kind "Haikelin" alkali derivant and its usage Download PDF

Info

Publication number
CN1125725A
CN1125725A CN94114057A CN94114057A CN1125725A CN 1125725 A CN1125725 A CN 1125725A CN 94114057 A CN94114057 A CN 94114057A CN 94114057 A CN94114057 A CN 94114057A CN 1125725 A CN1125725 A CN 1125725A
Authority
CN
China
Prior art keywords
derivative
selagine
physiological saline
haikelin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94114057A
Other languages
Chinese (zh)
Inventor
朱大元
唐烯灿
林金来
朱诚
沈竞康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN94114057A priority Critical patent/CN1125725A/en
Priority to AU42966/96A priority patent/AU4296696A/en
Priority to ES95941572T priority patent/ES2199259T3/en
Priority to US08/860,524 priority patent/US5929084A/en
Priority to DE69530706T priority patent/DE69530706T2/en
Priority to US09/799,127 priority patent/USRE38460E1/en
Priority to AT95941572T priority patent/ATE239708T1/en
Priority to JP52010296A priority patent/JP3545416B2/en
Priority to DK95941572T priority patent/DK0806416T3/en
Priority to PCT/CN1995/000100 priority patent/WO1996020176A1/en
Priority to PT95941572T priority patent/PT806416E/en
Priority to EP95941572A priority patent/EP0806416B1/en
Publication of CN1125725A publication Critical patent/CN1125725A/en
Priority to JP2003148129A priority patent/JP4105592B2/en
Priority to JP2007174592A priority patent/JP2007246545A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The "Haikelin" alkali derivative that can be used as efficient inhibitor of choline esterase with low toxicity is prepared by condensation reaction of "Haikelin" alkali with substituted acid chloride or aldehyde in anhydrous solvent.

Description

One class sea crin alkali derivant and its purposes
It is semi-synthetic to the present invention relates to natural product, is specifically related to alkaloid and its analogue.
The external anticholinesterase raising interior cholinergic system function measure treatment of the brain degenerative brain disorder of using is carried out big quantity research over nearly 10 years, though obtained gratifying result of study, but also there are many shortcomings, when therapeutic action occurring, more serious toxic reaction is arranged, and acting duration is shorter.
China separates from the herbal medicine Herba Lycopodii serrati and obtains new alkaloid selagine (11E)-5-amino-11-ethylidene-5,6,9,10-tetrahydrochysene-7-methyl-5,9-methylene cyclooctene is [b] pyridine-2 (1H)-ketone (Compound I) also for 5R, 9R in recent years
Figure A9411405700031
It has potent reversible anticholinesterase activity through the pharmacological research proof, to the selective restraining effect of acetylcholinesterase in the brain [United States Patent (USP) 5177082], selagine is carried out structure of modification and synthetic selagine analogue abroad, wish therefrom to find to have the method [United States Patent (USP) 4929731] of the compound [J.Org Chem 56 1991 (4636-4645)] of anticholinesterase activity and the complete synthesis selagine of searching but do not find good method as yet, also do not find the analogue of better effect.
It is semi-synthetic that the present invention utilizes the resources advantage of China's herbal medicine to design to carry out from selagine, wishes to seek out from many huperzine A derivatives compound better than existing huperzine alkali first effect and that toxicity is lower.
The present invention implements through the following steps:
From the Herba Lycopodii serrati plant through alcohols such as ethanol as extracting solvent, concentrated residue obtained water layer neutralizes with alkali through mineral acid (example hydrochloric acid) processing, and alkalization is (as ammoniacal liquor, NaOH) with organic solvent (as chloroform) extract total alkaloids, treated, chromatographic separation obtains compound (I).
2. compound (I) is through with corresponding replacement aldehyde or carry out condensation with corresponding replacement acyl chlorides in anhydrous solvent and get general formula (II) Y is Or-CHR is low alkyl, substituted-phenyl, substituted heterocyclic radical, replacement cinnamyl etc.
Sea crin alkali derivant:
Figure A9411405700051
The pharmacological action of huperzine A derivative:
The present invention uses the restraining effect of the colorimetric method for determining medicine of Ellman report to enzyme activity.Enzyme activity reaction solution total volume is 4ml, include acetylthiocholine iodide 0.3mmol/L (acetylcholinesterase substrate), or sulfur iodide is for the damping fluid 1ml of BuCh 0.4mmol/L (butyrylcholine esterase substrate) PH7.4 phosphoric acid salt 25mmol/L, add water at last and supply 4ml (comprising enzyme-added liquid measure in back and test soup), 37 ℃ of insulations are after 5 minutes, add enzyme liquid (rat erythrocyte membrane or rat blood serum) 0.1-0.2ml or add test soup 0.1-0.3ml simultaneously, be incubated 8 minutes again and add 1ml 3% sodium lauryl sulphate termination reaction, add 1ml 0.2% 5 at last, 5 '-connection sulphur-2,2 '-nitro-benzoic acid solution colour developing is measured optical density(OD) with " 721 " spectrophotometer in 440nm.With enzyme activity (the being 100%) contrast of unconstrained medicine, medicine molconcentration is mapped the drug dose IC when trying to achieve inhibitory enzyme vigor 50% with the percentage ratio of residual enzyme vigor 50Test-results shows: derivative No1, and No7, No8, No9 all has the obvious suppression effect to acetylcholinesterase, is weaker than selagine slightly, but obviously is better than Physostigmine and lycoremine.They are weaker than selagine to the restraining effect of butyrylcholine esterase (false enzyme), derivative No1 and No7 suppress to show greater than selagine (seeing Table I) enzyme dynamics to the selectivity of acetylcholinesterase, derivative No7, No8 and No9 are reversible with combining of acetylcholinesterase.
With the passive escape of mouse operation (diving tower method) and two kinds of memory models test shows of rat eight arm labyrinth spatial discriminations operations, derivative No8, No9 all have the very strong dysmnesia effect (seeing Table 2,3) that improves, and their action intensity is similar to compound (I).
The acute toxicity test of mouse shows, the LD of derivative No.8 and No.9 50Less than compound (I), only be the latter's 1/3 (seeing Table 4)
Table 1, the external anticholinesterase effect (colorimetric method for determining) of huperzine A derivative
Suppress 50% enzyme activity concentration (IC 50μ M) IC 50Ratio compd B uChE
Acetylcholinesterase butyrylcholine esterase AChENo (ACHE) (BUCHE) 1 0.348 380.19 1092.5 2 9.05＞346.7 3 3.63＞331.1 4＞12.88 58.9 5＞10.96＞275.4 6＞12.3＞309.1 7 0.172 199.5 1159.9 8 0.151 107.2 709.9 9 0.145 104.7 722.1 10＞15.85 109.6 11＞14.45 363 compounds (I), 0.06309 63.09 1000 eserine, 0.251 1.259 5.02 galanthamines, 1.995 12.59 6.3AChE takes from Rat Erythrocyte. BuChE takes from rat blood serum.
Table 2, huperzine A derivative improve the memory impairment of passive escape operation due to the scopolamine
Group dosage number of mice leave from office △ in latent period
(mg/kg ip+po) (only) (second ± SEM) physiological saline+physiological saline-+-20 71.9 ± 12.9 scopolamines+physiological saline 2+-20 29.5 ± 2.7 $$Scopolamine+derivative No8 2+0.2 20 67.7 ± 11.7**
2＋0.3 20 64.0±9.8＊
2+0.4 20 48.7 ± 6.9 physiological saline+physiological saline-+-18,81.7 ± 19.0 scopolamines+physiological saline 2+-23 32.3 ± 8.2 $$Scopolamine+derivative No9 2+0.1 11 48.9 ± 12.6
2＋0.2 16 71.6±14.5
2＋0.3 21 99.8±16.4＊＊
2+0.4 18 92.2 ± 15.5* △: mouse is administration immediately after training earlier, test after 24 hours. $$Compare * P＜0.05, * * P＜0.01 with physiological saline group comparison P＜0.01** and eastern gelsemium henbane group
Table 3, huperzine derivative improve spatial discrimination operative memory infringement due to the scopolamine
Wrong-way number of times △ group dosage number of mice before up to standard
(mg/kg) (only) reference memory working memory
Ip+po (X+SEM) physiological saline+physiological saline-+-24 0.42 ± 0.1 0.08 ± 0.01 scopolamine+physiological saline 0.2+-6 1.67 ± 0.21 $$2.33 ± 0.42 $$Scopolamine+derivative No9 0.2+0.1 6 1.33 ± 0.21 1.33 ± 0.49 *
0.2 ± 0.3 6 0.33 ± 0.21 *0.17 ± 0.17 *Physiological saline+physiological saline-+-24 0.33 ± 0.13 0.08 ± 0.06 scopolamine+physiological saline 0.125+-6 2.0 ± 0.45 $$2.0 ± 0.52 $$Scopolamine+derivative No8 0.125+0.2 6 0.67 ± 0.33 *0.33 ± 0.13 *Physiological saline+physiological saline-+-14 0.21 ± 0.11 0.07 ± 0.07 scopolamine+physiological saline 0.15+-7 2.14 ± 0.14 $$2.57 ± 0.29 $$Scopolamine+selagine 0.15+0.25 10 0.57 ± 0.30 *0.86 ± 0.14 *△: eight arm labyrinths test.Rat up to standard through training (every day errors number below 1 time, for three days on end) after, be used for test.It is the reference memory mistake that rat enters the arm of not putting foodstuff for the first time.It is the working memory mistake that rat repeats to enter the arm of putting foodstuff. $$Compare P＜0.01 with physiological saline group comparison P＜0.01** and eastern gelsemium henbane group.
Table 4, huperzine A derivative is to the acute toxicity (Bliss method) of mouse
Mg/kg p.o. (95% fiducial limit) * compound L D 5LD 5010 one group of compound (I) 3.1 (3.5-3.8) 4.6 (4.2-5.1) derivative No8 9.6 (7.3-12.5) 14.4 (12.8-16.4) derivative No9 11.1 (9.6-12.9) 14.1 (15.5-20.5) * mouse, ♀ ♂ half and half.Each medicine is tested with 4-5 dosage groups.
Observe the mortality ratio in 7 days.
Above-mentioned pharmacological experiments shows derivative No7, and No8, No9 are potent acetylcholinesterase selective depressants, and its acute toxicity is lower than compound (I), and therefore, they have the clinical application DEVELOPMENT PROSPECT inference.Be used for the treatment of the memory dysfunction that alleviation myasthenia gravis and central cholinergic system nonfunction cause.
Embodiment 1, the preparation of derivative No.2
Take by weighing compound (I) (0.50mmole) in the 50ml three-necked bottle, add the 20ml anhydrous pyridine, make (I) compound dissolution, ice under the molten cooling, splash into phenyllacetyl chloride (0.55mmole), after dropping was finished, room temperature was placed (25 ℃) the thin plate chromatography that spends the night and is shown that raw material disappears substantially, stopped reaction, water pump pressure reducing and steaming pyridine, separate with methylene dichloride with silica gel column chromatography: acetone: methyl alcohol=50: 45: 5 Xian take off thick product, acetone, sherwood oil mixed solvent recrystallization get product, yield 75%.UV λ mox1＝229nm(ε＝17360)
λ mox2＝316nm(ε＝9320)[α] D 25℃＝29.43° 1HNMR： 2H?6.31(1H，d，δ2，3＝9.9HZ)[CDDCl 3]?3H?7.20(1H，d，δ2，3＝9.9HZ)(400MHZ)?6H?2.89(1H?dd)
7H?3.52(1H?m)
8H?5.38(1H?d)
10-H?1.62(3H?d，J 10，11＝6.7HZ)
11-H?5.08(1H?σ，J 10，11＝6.7HZ)
14-H?2.15，2.45(2H)，16-H，1.50(3H，S)
2’，6’-H?7.36(2H，d)
3’，5’-H?7.29(2H，m)
6’-H?7.24(1H，m)
7’-H?3.59(S)MS(m/z)360(M +)345?269?252?227?224?210(100％)91mp： 171—173℃IR：(υ，cm -1)3280，1660(S)，1620(S)，1550，1450，1350，1300，
1175，1130，840，620
Can make derivative No.1, No.5, No.6, No.10, No.11 with method.
Embodiment 2, the preparation of derivative No4
Take by weighing compound (I) (0.5mmole) in the 50ml three-necked bottle, add the 20ml anhydrous pyridine, make its dissolving, under the molten cooling of ice, add DBU (0.66mmole) earlier, 2-formyl chloride the pyridine hydrochloride that adds 0.55mmole again, room temperature is placed and is spent the night, show that with the thin plate measurement in chromatography reaction is complete substantially, with water pump pressure reducing and steaming pyridine, separate with silica gel column chromatography, developping agent is a methylene dichloride: acetone: methyl alcohol=Xian took off in 50: 45: 5, get thick product, get product yield 74% with acetone, sherwood oil mixed solvent recrystallization.UV λ mox＝226nm(ε＝1.35×10 4)
λ mox＝264nm(ε＝5.4×10 3)
λ mox＝315nm(ε＝5730)[α] D＝77.85° 1HNMR：2H?6.36(1H，δ2.3＝9.2HZ)[CDCl 3]3-H?7.44(1H，δ2，3＝9.2HZ)(400MHZ)6-H?3.05(1H?dd)
7-H?3.74(1H?m)
8-H?5.42(1H?d)
10-H?1.65(3H?d，δ 10-11＝6.6HZ)
11-H?5.35(1H?d，δ 10-11＝6.6HZ)
14-H?2.42(2H)
16-H?1.55(S)
3’-H?8.58(1H，d)
4’-H?7.85(1H，q)
5’7.48(1H，m)
6’8.15(1H，d)MS(m/z)348(M +＋1)347(M +)241(100％)169，149，106，95，79，
71，55mp： 170—171℃IR：(υ，cm -1)3450cm -1，2900，1660(S)，1615(S)，1530(S)，1460，
1300，1180，1140，1000，830，750
Embodiment 3, the preparation of derivative No8
Taking by weighing compound (I) (0.5mmole) is put in the 50ml three-necked flask, add dehydrated alcohol, add 4-methoxyl group, 5-hydroxy benzaldehyde (0.51mmole) reflux slightly, constantly steam part ethanol through water trap, and the solvent in the postreaction at any time, stoichiometric number hour is also used its reaction condition of thin plate measurement in chromatography at any time, treat fully after, ethanol is removed in decompression, get solid, product acetone, sherwood oil mixed solvent recrystallization get product, productive rate 92%.

Claims (3)

1. extra large crin alkali derivant that structural formula is following Wherein Y is
Figure A9411405700022
Or-CII
R is low alkyl, substituted-phenyl, substituted heterocyclic radical, replacement cinnamyl.
2.. compound according to claim 1 is characterized in that its preparation method is:
(1) as Y is The time, selagine and corresponding replacement acyl chlorides carry out condensation in anhydrous solvent,
(2) when Y be-during HC, then the aldehyde of selagine and corresponding replacement carries out condensation in anhydrous solvent.
3. huperzine A derivative according to claim 1 is characterized in that it is the true cholinesterase selective depressant, can be used for treatment and alleviates myasthenia gravis, memory dysfunction that the central cholinergic system nonfunction causes and glaucoma.
CN94114057A 1994-12-28 1994-12-28 First-kind "Haikelin" alkali derivant and its usage Pending CN1125725A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN94114057A CN1125725A (en) 1994-12-28 1994-12-28 First-kind "Haikelin" alkali derivant and its usage
JP52010296A JP3545416B2 (en) 1994-12-28 1995-12-26 Huperzine A derivatives, their production and their use
DK95941572T DK0806416T3 (en) 1994-12-28 1995-12-26 Huperzine derivatives, their preparation and use
US08/860,524 US5929084A (en) 1994-12-28 1995-12-26 Huperzine A derivatives, their preparation and their use
DE69530706T DE69530706T2 (en) 1994-12-28 1995-12-26 HUPERZINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE
US09/799,127 USRE38460E1 (en) 1994-12-28 1995-12-26 Huperzine A derivatives, their preparation and their use
AT95941572T ATE239708T1 (en) 1994-12-28 1995-12-26 HUPERZINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE
AU42966/96A AU4296696A (en) 1994-12-28 1995-12-26 Huperzine a derivatives, their preparation and their use
ES95941572T ES2199259T3 (en) 1994-12-28 1995-12-26 DERIVATIVES OF HUPERZINA, ITS PREPARATION AND ITS USE.
PCT/CN1995/000100 WO1996020176A1 (en) 1994-12-28 1995-12-26 Huperzine a derivatives, their preparation and their use
PT95941572T PT806416E (en) 1994-12-28 1995-12-26 HUPERZINE DERIVATIVES TO ITS PREPARATION AND UTILIZATION
EP95941572A EP0806416B1 (en) 1994-12-28 1995-12-26 Huperzine a derivatives, their preparation and their use
JP2003148129A JP4105592B2 (en) 1994-12-28 2003-05-26 Huperzine A derivatives, their preparation and their use
JP2007174592A JP2007246545A (en) 1994-12-28 2007-07-02 Huperzine a derivative, method for producing the same and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN94114057A CN1125725A (en) 1994-12-28 1994-12-28 First-kind "Haikelin" alkali derivant and its usage

Publications (1)

Publication Number Publication Date
CN1125725A true CN1125725A (en) 1996-07-03

Family

ID=5037011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94114057A Pending CN1125725A (en) 1994-12-28 1994-12-28 First-kind "Haikelin" alkali derivant and its usage

Country Status (11)

Country Link
US (1) US5929084A (en)
EP (1) EP0806416B1 (en)
JP (3) JP3545416B2 (en)
CN (1) CN1125725A (en)
AT (1) ATE239708T1 (en)
AU (1) AU4296696A (en)
DE (1) DE69530706T2 (en)
DK (1) DK0806416T3 (en)
ES (1) ES2199259T3 (en)
PT (1) PT806416E (en)
WO (1) WO1996020176A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308312C (en) * 2003-11-13 2007-04-04 中国科学院上海药物研究所 Huperzine B bimolecular and double function group devicative, preparing method and its use
CN100398093C (en) * 2003-03-14 2008-07-02 德比欧药物研究有限公司 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
CN100528844C (en) * 2007-04-20 2009-08-19 中国科学院昆明植物研究所 Huperzine A derivative, preparation method and application thereof
CN101797223B (en) * 2009-02-06 2012-05-23 上海交通大学医学院 Huperzine A preparations for eyes and application thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
NL1009437C2 (en) * 1998-06-18 1999-12-21 Xenobiosis Extraction process.
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
US6159986A (en) * 1999-11-02 2000-12-12 Altman; David A. Compounds and therapy for resisting memory loss in humans
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
CA2408148A1 (en) * 2000-05-05 2001-11-15 United States Army Medical Research And Materiel Command Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
KR100390777B1 (en) * 2000-12-19 2003-07-10 한국화학연구원 A process for preparing pyridone derivative
DE10144041B9 (en) * 2001-09-07 2012-07-26 Leica Mikrosysteme Gmbh Device for the automatic feeding of slides to a coverslipper
BRPI0407818A (en) * 2003-03-14 2006-02-14 Debio Rech Pharma Sa subcutaneous distribution system, process for its preparation and use for the treatment of cholinergic deficiency diseases
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP3056200B1 (en) 2005-05-23 2023-09-06 President and Fellows of Harvard College Huperzine for use in treating seizure
US20070179123A1 (en) * 2005-11-08 2007-08-02 Chiang Peter K Methods and compositions for treating diseases associated with pathogenic proteins
CA2650711A1 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US8097726B2 (en) * 2006-05-17 2012-01-17 Industrial Technology Research Institute Huperzine a compound for treatment of alzheimer's disease
EP2044937A4 (en) * 2006-07-05 2010-10-27 Tianjin Hemay Bio Tech Co Ltd ANALGESIC 5, 9 - METHANOCYCLOOCTA (b) PYRIDIN - 2 (1H) - ONE DERIVATIVES, THEIR PREPARATION METHOD AND USE
TWI404531B (en) * 2007-05-17 2013-08-11 Ind Tech Res Inst Huperzine a compound and pharmaceutical composition comprising the same
WO2010028134A2 (en) * 2008-09-04 2010-03-11 President And Fellows Of Harvard College Treatment of neurological disorders using huperzine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177082A (en) * 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4929731A (en) * 1989-02-21 1990-05-29 University Of Pittsburgh Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
US5684018A (en) * 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100398093C (en) * 2003-03-14 2008-07-02 德比欧药物研究有限公司 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
CN1308312C (en) * 2003-11-13 2007-04-04 中国科学院上海药物研究所 Huperzine B bimolecular and double function group devicative, preparing method and its use
CN100528844C (en) * 2007-04-20 2009-08-19 中国科学院昆明植物研究所 Huperzine A derivative, preparation method and application thereof
CN101797223B (en) * 2009-02-06 2012-05-23 上海交通大学医学院 Huperzine A preparations for eyes and application thereof

Also Published As

Publication number Publication date
ES2199259T3 (en) 2004-02-16
DE69530706D1 (en) 2003-06-12
AU4296696A (en) 1996-07-19
PT806416E (en) 2003-09-30
EP0806416A1 (en) 1997-11-12
JP2007246545A (en) 2007-09-27
DK0806416T3 (en) 2003-09-01
DE69530706T2 (en) 2004-03-25
JP4105592B2 (en) 2008-06-25
US5929084A (en) 1999-07-27
WO1996020176A1 (en) 1996-07-04
EP0806416B1 (en) 2003-05-07
ATE239708T1 (en) 2003-05-15
JPH10511651A (en) 1998-11-10
JP3545416B2 (en) 2004-07-21
JP2003306481A (en) 2003-10-28
EP0806416A4 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
CN1125725A (en) First-kind "Haikelin" alkali derivant and its usage
EP2488531B1 (en) Synthetic methods for spiro-oxindole compounds
KR101922266B1 (en) Selective glycosidase inhibitors and uses thereof
Stocking et al. Total Synthesis of VM55599. Utilization of an Intramolecular Diels− Alder Cycloaddition of Potential Biogenetic Relevance
EP1078928B1 (en) Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
KR102556482B1 (en) Tetrahydroisoquinoline-based compound, method for preparing the same, drug composition containing the tetrahydroisoquinoline-based compound and use thereof
CN101948430A (en) Sinomenine derivative and preparation method and applications thereof
EP2268644B1 (en) Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2486013B1 (en) Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
CN106883225B (en) It is a kind of with 1,2,4- oxadiazoles-structure fragment coumarin derivative and its application
CN102159562A (en) Chromene modulators of chemokine receptor activity
USRE38460E1 (en) Huperzine A derivatives, their preparation and their use
CN114230582A (en) Novel securinine dimer and preparation method and application thereof
US7119213B2 (en) Pharmacologically active isolated or purified dauer pheromone compound for controlling aging and stress and method for isolating and characterizing the same
CN105906598A (en) Chrysin derivative as well as preparation method and application thereof
RU2792034C2 (en) Tetrahydroisoquinoline compound, its production method, pharmaceutical composition containing such a compound, and its use
AU781663B2 (en) New pyrimidin-4-one compounds, a process for their preparation and pharmaceutical compositions containing them
CN103242214A (en) Indole derivative and preparation method thereof
US4943589A (en) Anthelmintic dysinins of marine origin
KR100746939B1 (en) N-[1'-substituted sulfonamide-spiro(2h-1-benzopyrane-2,4-piperidin) -6-yl]substituted amine derivatives, process for preparation and use thereof
CN102666486A (en) Azabicyclo octane derivatives, preparation process and pharmaceutical use thereof
AU762990B2 (en) New benzo(3,4)cyclobuta(1,2-C)pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
CN115650972A (en) Sophoridine derivative and preparation method and application thereof
JPH06256366A (en) Novel lysophosphatidyl inositol and its production
CN101029064A (en) Helicid analogue and application thereof in preparing anti-senile dementia medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication